Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety and effectiveness of zimberelimab combined with
metformin in treating relapsed/persistent ovarian clear cell carcinoma.